Tumors with ICOS expression on tumor‐infiltrating CD4 and CD8 T cells may benefit from an ICOS agonist whereas tumors that express high levels of ICOS on Tregs may benefit from an ICOS inhibitor. Here, CD8A is linked to neoplasm.